tetano
Editor, Senior Moderator
Virus Res. 2015 Sep 9. pii: S0168-1702(15)30060-5. doi: 10.1016/j.virusres.2015.09.005. [Epub ahead of print]
[h=1]Lactobacillus plantarum vaccine vector expressing hemagglutinin provides protection against H9N2 challenge infection.[/h] Shi SH[SUP]1[/SUP], Yang WT[SUP]1[/SUP], Yang GL[SUP]1[/SUP], Zhang XK[SUP]2[/SUP], Liu YY[SUP]1[/SUP], Zhang LJ[SUP]1[/SUP], Ye LP[SUP]1[/SUP], Hu JT[SUP]1[/SUP], Xin-Xing[SUP]1[/SUP], Qi C[SUP]3[/SUP], Li Y[SUP]1[/SUP], Wang CF[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Hemagglutinin (HA) has been demonstrated as an effective candidate vaccine antigen against AIVs. Dendritic cell-targeting peptide (DCpep) can enhance the robustness of immune responses. The purpose of this study was to evaluate whether DCpep could enhance the immune response against H9N2 AIV when utilizing Lactobacillus plantarum NC8 (NC8) to present HA-DCpep in mouse and chicken models. To accomplish this, a mucosal vaccine of a recombinant NC8 strain expressing HA and DCpep that was constructed in a previous study was employed. Orally administered NC8-pSIP409-HA-DCpep elicited high serum titers of hemagglutination-inhibition (HI) antibodies in mice and also induced robust T cell immune responses in both mouse and chicken models. Orally administered NC8-pSIP409-HA-DCpep elicited high serum titers of hemagglutination-inhibition (HI) antibodies in mice and also induced robust T cell immune responses in both mouse and chicken models. These results revealed that recombinant L. plantarum NC8-pSIP409-HA-DCpep is an effective vaccine candidate against H9N2 AIVs.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Dendritic cell-targeting peptide; H9N2 influenza virus; Hemagglutinin; Lactobacillus plantarum; Mucosal vaccination
PMID: 26363195 [PubMed - as supplied by publisher]
[h=1]Lactobacillus plantarum vaccine vector expressing hemagglutinin provides protection against H9N2 challenge infection.[/h] Shi SH[SUP]1[/SUP], Yang WT[SUP]1[/SUP], Yang GL[SUP]1[/SUP], Zhang XK[SUP]2[/SUP], Liu YY[SUP]1[/SUP], Zhang LJ[SUP]1[/SUP], Ye LP[SUP]1[/SUP], Hu JT[SUP]1[/SUP], Xin-Xing[SUP]1[/SUP], Qi C[SUP]3[/SUP], Li Y[SUP]1[/SUP], Wang CF[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Hemagglutinin (HA) has been demonstrated as an effective candidate vaccine antigen against AIVs. Dendritic cell-targeting peptide (DCpep) can enhance the robustness of immune responses. The purpose of this study was to evaluate whether DCpep could enhance the immune response against H9N2 AIV when utilizing Lactobacillus plantarum NC8 (NC8) to present HA-DCpep in mouse and chicken models. To accomplish this, a mucosal vaccine of a recombinant NC8 strain expressing HA and DCpep that was constructed in a previous study was employed. Orally administered NC8-pSIP409-HA-DCpep elicited high serum titers of hemagglutination-inhibition (HI) antibodies in mice and also induced robust T cell immune responses in both mouse and chicken models. Orally administered NC8-pSIP409-HA-DCpep elicited high serum titers of hemagglutination-inhibition (HI) antibodies in mice and also induced robust T cell immune responses in both mouse and chicken models. These results revealed that recombinant L. plantarum NC8-pSIP409-HA-DCpep is an effective vaccine candidate against H9N2 AIVs.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Dendritic cell-targeting peptide; H9N2 influenza virus; Hemagglutinin; Lactobacillus plantarum; Mucosal vaccination
PMID: 26363195 [PubMed - as supplied by publisher]